OBJECTIVE: G(M2) gangliosidoses are caused by an inherited deficiency of lysosomal β-hexosaminidase and result in ganglioside accumulation in the brain. Onset during infancy leads to rapid neurodegeneration and death before 4 years of age. We set out to quantify the rate of functional decline in infantile G(M2) gangliosidosis on the basis of patient surveys and a comprehensive review of existing literature. METHODS: Patients with infantile G(M2) gangliosidosis (N = 237) were surveyed via questionnaire by the National Tay Sachs & Allied Diseases Association (NTSAD). These data were supplemented by survival data from the NTSAD database and a literature survey. Detailed retrospective surveys from 97 patients were available. Five patients who had received hematopoietic stem cell transplantation were evaluated separately. The mortality rate of the remaining 92 patients was comparable to that of the 103 patients from the NTSAD database and 121 patients reported in the literature. RESULTS: Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%). All 55 patients who had learned to sit without support lost that ability within 1 year. Individual functional measures correlated with each other but not with survival. Gastric tube placement was associated with prolonged survival. Tay Sachs and Sandhoff variants did not differ. Hematopoietic stem cell transplantation was not associated with prolonged survival. CONCLUSIONS: We studied the timing of regression in 97 cases of infantile G(M2) gangliosidosis and conclude that clinical disease progression does not correlate with survival, likely because of the impact of improved supportive care over time. However, functional measures are quantifiable and can inform power calculations and study design of future interventions.
OBJECTIVE: G(M2) gangliosidoses are caused by an inherited deficiency of lysosomal β-hexosaminidase and result in ganglioside accumulation in the brain. Onset during infancy leads to rapid neurodegeneration and death before 4 years of age. We set out to quantify the rate of functional decline in infantile G(M2) gangliosidosis on the basis of patient surveys and a comprehensive review of existing literature. METHODS:Patients with infantile G(M2) gangliosidosis (N = 237) were surveyed via questionnaire by the National Tay Sachs & Allied Diseases Association (NTSAD). These data were supplemented by survival data from the NTSAD database and a literature survey. Detailed retrospective surveys from 97 patients were available. Five patients who had received hematopoietic stem cell transplantation were evaluated separately. The mortality rate of the remaining 92 patients was comparable to that of the 103 patients from the NTSAD database and 121 patients reported in the literature. RESULTS: Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%). All 55 patients who had learned to sit without support lost that ability within 1 year. Individual functional measures correlated with each other but not with survival. Gastric tube placement was associated with prolonged survival. Tay Sachs and Sandhoff variants did not differ. Hematopoietic stem cell transplantation was not associated with prolonged survival. CONCLUSIONS: We studied the timing of regression in 97 cases of infantile G(M2) gangliosidosis and conclude that clinical disease progression does not correlate with survival, likely because of the impact of improved supportive care over time. However, functional measures are quantifiable and can inform power calculations and study design of future interventions.
Authors: Orit Neudorfer; Gregory M Pastores; Bai J Zeng; John Gianutsos; Charles M Zaroff; Edwin H Kolodny Journal: Genet Med Date: 2005-02 Impact factor: 8.822
Authors: Diane Golebiowski; Imramsjah M J van der Bom; Churl-Su Kwon; Andrew D Miller; Keiko Petrosky; Allison M Bradbury; Stacy Maitland; Anna Luisa Kühn; Nina Bishop; Elizabeth Curran; Nilsa Silva; Dwijit GuhaSarkar; Susan V Westmoreland; Douglas R Martin; Matthew J Gounis; Wael F Asaad; Miguel Sena-Esteves Journal: Hum Gene Ther Date: 2017-01-26 Impact factor: 5.695
Authors: Jeanine R Jarnes Utz; Sarah Kim; Kelly King; Richard Ziegler; Lynn Schema; Evelyn S Redtree; Chester B Whitley Journal: Mol Genet Metab Date: 2017-04-29 Impact factor: 4.797
Authors: Jeanine R Jarnes Utz; Thomas Crutcher; Joseph Schneider; Patrick Sorgen; Chester B Whitley Journal: Mol Genet Metab Date: 2014-12-06 Impact factor: 4.797
Authors: Karolina M Stepien; Su Han Lum; J Edmond Wraith; Christian J Hendriksz; Heather J Church; David Priestman; Frances M Platt; Simon Jones; Ana Jovanovic; Robert Wynn Journal: JIMD Rep Date: 2017-12-07
Authors: Allison M Bradbury; Heather L Gray-Edwards; Jamie L Shirley; Victoria J McCurdy; Alexandria N Colaco; Ashley N Randle; Pete W Christopherson; Allison C Bird; Aime K Johnson; Diane U Wilson; Judith A Hudson; Nicholas L De Pompa; Donald C Sorjonen; Brandon L Brunson; Mylvaganam Jeyakumar; Frances M Platt; Henry J Baker; Nancy R Cox; Miguel Sena-Esteves; Douglas R Martin Journal: Exp Neurol Date: 2014-10-05 Impact factor: 5.330